NEW YORK (GenomeWeb) – Oxford Cancer Biomarkers (OCB) announced today that it has licensed its suite of in vitro colorectal cancer diagnostics to Chinese precision medicine firm My-BioMed Biotechnology (MBM).

Under the terms of the deal, MBM will have access to OCB's ColoTox, ColoProg, and ColoPredict tests and technologies, which will be offered in China through a purpose-built biomedical laboratory. Additional terms were not disclosed.